JP Morgan Chase’s GT Biopharma GTBP Stock Holding History

JP Morgan Chase’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	1	–	–	﹤0.01%	7879
2026 Q1	$0	Hold	1	–	–	﹤0.01%	7682
2025 Q4	$1	Hold	1	–	–	﹤0.01%	7379
2025 Q3	$1	Hold	1	–	–	﹤0.01%	7354
2025 Q2	$4	Hold	1	–	–	﹤0.01%	7004
2025 Q1	$2	Hold	1	–	–	﹤0.01%	7251
2024 Q4	$3	Hold	1	–	–	﹤0.01%	7346
2024 Q3	$2	Hold	1	–	–	﹤0.01%	7355
2024 Q2	$3	Hold	1	–	–	﹤0.01%	7264
2024 Q1	$4	Hold	1	–	–	﹤0.01%	7281
2023 Q4	$4	Sell	1 -1	-50%	-$7	﹤0.01%	7456
2023 Q3	$14	Sell	2 -85	-98%	-$703	﹤0.01%	7245
2023 Q2	$810	Buy	87 +86	+8,600%	+$892	﹤0.01%	6486
2023 Q1	$0	Hold	1	–	–	﹤0.01%	6921
2022 Q4	$0	Hold	1	–	–	﹤0.01%	6730
2022 Q3	$0	Hold	1	–	–	﹤0.01%	6609
2022 Q2	$0	Sell	1 -277	-100%	-$21K	﹤0.01%	6636
2022 Q1	$24K	Buy	278 +50	+22%	+$4.41K	﹤0.01%	6030
2021 Q4	$21K	Hold	228	–	–	﹤0.01%	6198
2021 Q3	$46K	Sell	228 -77	-25%	-$23.2K	﹤0.01%	5860
2021 Q2	$142K	Buy	+305	New	+$127K	﹤0.01%	5403

Other funds holding GTBP

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EFG

Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

OWA

Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return

4WM

49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Kitching Partners Conshohocken, Pennsylvania $116M AUM 16.12% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $20.5B AUM 24.45% 1-Year Est. Return

JP Morgan Chase's GTBP Position: Q2 2026 in Review

JP Morgan Chase held its GT Biopharma (GTBP) position steady in Q2 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7879.

JP Morgan Chase first reported a position in GTBP in Q2 2021 and has held it in 21 quarters since. The position peaked at $142K in Q2 2021. 41 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

JP Morgan Chase held 1 share of GT Biopharma worth $0 as of Q2 2026.
JP Morgan Chase left its GT Biopharma share count unchanged in Q2 2026.
GT Biopharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7879 holding.
JP Morgan Chase first reported a position in GT Biopharma in Q2 2021 and has held it in 21 quarters since.
JP Morgan Chase's GT Biopharma position peaked at $142K in Q2 2021.
41 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.